9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.

Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 12

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Safety and tolerability of HSV1716 given by single and repeat intrapleural administration in patients with inoperable malignant pleural mesothelioma.,  Obtain evidence of HSV1716 replication and lysis of malignant pleural mesothelioma cells through analysis of pleural fluid and serum samples for evidence of cell death and/or HSV1716 replication and/or changes in appropriate biomarkers.,  ,

Interventions: HSV1716 Intra-pleural delivery,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: November 14, 2016

Completion Date: November 14, 2016

Last  Posted Date: June 9, 2017

Location: Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom

Website Link: https://ClinicalTrials.gov/show/NCT01721018

Was this article helpful?
Dislike 0